Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuanghuang Shengbai Oral Liquid for chemotherapy-induced grade I-II neutropenia in non-small cell lung adenocarcinoma
ChiCTR2300072046Phase 2Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of shuanghuang shengbai in Non-small cell lung cancer adenocarcinoma (NSCLC) and chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Neutrophils. Planned start May 2023; status: not yet recruiting.
02
Drugs
shuanghuang shengbai
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR2300072046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072046.